Use of Dipeptidyl Peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: a propensity score analysis from the CORONADO study.
| Author | |
|---|---|
| Abstract |
:
Dipeptidyl Peptidase-4 (DPP-4), the target of oral antidiabetic drugs DDP-4 inhibitors, has been suggested to be involved in the pathogenesis of coronavirus infections, including COVID-19. It is unclear whether the routine use of DPP-4 inhibitors increases the severity of COVID-19 in people with type 2 diabetes (T2D). Our purpose was to investigate the association between routine use of DPP-4 inhibitors and the severity of COVID-19 infection in a large multicentric study. |
| Year of Publication |
:
2021
|
| Journal |
:
Diabetes, obesity & metabolism
|
| Date Published |
:
2021
|
| ISSN Number |
:
1462-8902
|
| URL |
:
https://doi.org/10.1111/dom.14324
|
| DOI |
:
10.1111/dom.14324
|
| Short Title |
:
Diabetes Obes Metab
|
| Download citation |
